JP2009506985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009506985A5 JP2009506985A5 JP2008521907A JP2008521907A JP2009506985A5 JP 2009506985 A5 JP2009506985 A5 JP 2009506985A5 JP 2008521907 A JP2008521907 A JP 2008521907A JP 2008521907 A JP2008521907 A JP 2008521907A JP 2009506985 A5 JP2009506985 A5 JP 2009506985A5
- Authority
- JP
- Japan
- Prior art keywords
- plexin
- use according
- binding molecule
- molecule
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001094868 Homo sapiens Plexin-D1 Proteins 0.000 claims 26
- 102100035380 Plexin-D1 Human genes 0.000 claims 26
- 102000002022 plexin Human genes 0.000 claims 10
- 108050009312 plexin Proteins 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000012636 effector Substances 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002452 interceptive effect Effects 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108091008102 DNA aptamers Proteins 0.000 claims 1
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108091008103 RNA aptamers Proteins 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical group [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 claims 1
- 108010000499 Thromboplastin Proteins 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229960004395 bleomycin sulfate Drugs 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 229940006110 gallium-67 Drugs 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000575 polymersome Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940056501 technetium 99m Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05076675 | 2005-07-21 | ||
| PCT/EP2006/007241 WO2007009816A2 (en) | 2005-07-21 | 2006-07-20 | Plexin d1 as a target for tumor diagnosis and therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009506985A JP2009506985A (ja) | 2009-02-19 |
| JP2009506985A5 true JP2009506985A5 (https=) | 2009-09-03 |
Family
ID=37115996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008521907A Pending JP2009506985A (ja) | 2005-07-21 | 2006-07-20 | 腫瘍の診断及び治療のための標的としてのプレキシンｄ１ |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20100119445A1 (https=) |
| EP (1) | EP1907420B1 (https=) |
| JP (1) | JP2009506985A (https=) |
| CN (1) | CN101287758A (https=) |
| AU (1) | AU2006271880A1 (https=) |
| BR (1) | BRPI0613425A2 (https=) |
| CA (1) | CA2615744C (https=) |
| DK (1) | DK1907420T3 (https=) |
| ES (1) | ES2632360T3 (https=) |
| IL (1) | IL188688A0 (https=) |
| PL (1) | PL1907420T3 (https=) |
| WO (1) | WO2007009816A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090181035A1 (en) * | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| US8512944B2 (en) * | 2008-08-27 | 2013-08-20 | Oncotherapy Science, Inc. | PRMT1 for target genes of cancer therapy and diagnosis |
| CN101914542B (zh) * | 2009-04-28 | 2013-03-06 | 中国科学院化学研究所 | 用于不同亚型非小细胞肺癌分型的一种核酸适体及其筛选方法 |
| EP2385121A1 (en) * | 2010-05-06 | 2011-11-09 | Netris Pharma | Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents |
| EP2487242A1 (en) | 2011-02-09 | 2012-08-15 | Ruprecht-Karls-Universität Heidelberg | B-type plexin antagonists and uses thereof |
| CA2912801A1 (en) * | 2013-05-17 | 2014-11-20 | Medimmune, Llc | Receptors for b7-h4 |
| US11066462B2 (en) | 2014-12-11 | 2021-07-20 | Citryll B.V. | Method for the treatment of idiopathic pulmonary fibrosis |
| CN106967789A (zh) * | 2017-01-26 | 2017-07-21 | 上海长海医院 | 一种前列腺癌标志物plxna1及其应用 |
| WO2018190365A1 (ja) * | 2017-04-12 | 2018-10-18 | 国立大学法人九州大学 | 神経障害性疼痛マーカー及びその使用 |
| EP3693380A1 (en) | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| CN117659171B (zh) * | 2022-09-07 | 2024-10-22 | 东莞市朋志生物科技有限公司 | 抗HBeAg抗体或其功能性片段、检测HBeAg的试剂和试剂盒 |
| CN116459356B (zh) * | 2023-04-24 | 2024-03-19 | 中国人民解放军总医院第一医学中心 | 用于动脉粥样硬化斑块早期预警和动态监测的多模态分子成像纳米探针及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| WO2001014420A2 (en) * | 1999-08-25 | 2001-03-01 | University Of Torino | Novel members of the plexin family and uses thereof |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| WO2001090190A2 (en) * | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| EP2236614A3 (en) * | 2002-08-15 | 2011-01-26 | Genzyme Corporation | Brain endothelial cell expression patterns |
| SE0203137D0 (sv) * | 2002-10-24 | 2002-10-24 | Karolinska Innovations Ab | Drug target in cancer therapy |
| AU2003292231A1 (en) * | 2002-12-12 | 2004-06-30 | Novartis Ag | Methods for diagnosing and treating schizophrenia |
| CA2519630A1 (en) * | 2003-03-20 | 2004-10-07 | Dana-Farber Cancer Institute, Inc. | Gene expression in breast cancer |
| EP1679372B1 (en) * | 2003-10-30 | 2009-02-18 | Kazusa DNA Research Institute Foundation | Novel plexin polypeptide, dna encoding the same and use thereof |
| DE102004037860A1 (de) * | 2004-08-04 | 2006-03-16 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen |
-
2006
- 2006-07-20 CN CNA2006800303915A patent/CN101287758A/zh active Pending
- 2006-07-20 EP EP06776353.2A patent/EP1907420B1/en not_active Not-in-force
- 2006-07-20 AU AU2006271880A patent/AU2006271880A1/en not_active Abandoned
- 2006-07-20 WO PCT/EP2006/007241 patent/WO2007009816A2/en not_active Ceased
- 2006-07-20 ES ES06776353.2T patent/ES2632360T3/es active Active
- 2006-07-20 US US11/996,166 patent/US20100119445A1/en not_active Abandoned
- 2006-07-20 PL PL06776353T patent/PL1907420T3/pl unknown
- 2006-07-20 DK DK06776353.2T patent/DK1907420T3/en active
- 2006-07-20 BR BRPI0613425-4A patent/BRPI0613425A2/pt not_active Application Discontinuation
- 2006-07-20 JP JP2008521907A patent/JP2009506985A/ja active Pending
- 2006-07-20 CA CA2615744A patent/CA2615744C/en active Active
-
2008
- 2008-01-09 IL IL188688A patent/IL188688A0/en unknown
-
2012
- 2012-07-03 US US13/541,296 patent/US9422358B2/en not_active Expired - Fee Related
-
2016
- 2016-07-14 US US15/210,676 patent/US9988449B2/en active Active
-
2018
- 2018-05-03 US US15/970,116 patent/US20180319882A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009506985A5 (https=) | ||
| Walkey et al. | Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment | |
| AU2015213483B2 (en) | Aptamer construct | |
| EP1960790B1 (en) | Annexin derivatives suitable for pretargeting in therapy and diagnosis | |
| JP2011525354A5 (https=) | ||
| Rosenfeld et al. | Nanobodies targeting prostate-specific membrane antigen for the imaging and therapy of prostate cancer | |
| JP2013116897A5 (https=) | ||
| US10900969B2 (en) | Biomimetic microfluid device for capturing circulating tumor cells | |
| JP2019511201A5 (https=) | ||
| RU2017143633A (ru) | Биологические материалы и способы их применения | |
| JP2008503217A5 (https=) | ||
| Pechar et al. | The coiled coil motif in polymer drug delivery systems | |
| JP2011502517A5 (https=) | ||
| Chauhan et al. | Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC) | |
| CA3091126A1 (en) | Nanopore assemblies and uses thereof | |
| Tan et al. | Selection and identification of transferrin receptor-specific peptides as recognition probes for cancer cells | |
| WO2012016713A1 (en) | Tumour targeting with polypeptides | |
| RU2442169C2 (ru) | Система магнитного распознавания | |
| RU2003123100A (ru) | Специфические антитела человека для селективной терапии рака | |
| JP2005528884A5 (https=) | ||
| US20200223893A1 (en) | Therapeutic nanoconjugates and uses thereof | |
| JP2014515600A5 (https=) | ||
| JP2009515897A5 (https=) | ||
| JP2008538182A5 (https=) | ||
| JP2011504361A (ja) | 肝細胞癌細胞に特異的なペプチドおよびその適用 |